BLASUBCUTANEOUSINJECTABLE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) by Roche is her2/neu/cerbb2 antagonists [moa]. First approved in 2020.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHESGO is a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase administered subcutaneously for HER2-positive breast cancer. It combines two monoclonal antibodies targeting HER2/Neu with an endoglycosidase to enable subcutaneous delivery, improving patient convenience over intravenous administration. The drug is indicated for breast cancer treatment and represents a significant advancement in HER2-directed therapy.
$1MPart D
PeakPHESGO is in peak lifecycle with modest Part D spending ($1M, 139 claims), suggesting a niche market position; the commercial team is likely focused on market penetration and specialty pharmacy channels rather than rapid expansion.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
Started Jul 2024
165 enrolled
HER2-positive Breast Cancer
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Started Sep 2023
230 enrolled
Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Started Jul 2022
922 enrolled
Locally Advanced or Metastatic Breast Cancer
Worked on PHESGO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.